The attitude of gynecologists in São Paulo, Brazil 3 years after the Women's Health Initiative study

Maturitas

Volumn 56, Issue 2, 2007, Pages 129-141

  Lazar Jr , Felipe ^a   Costa Paiva, Lucia ^a   Morais, Sirlei S ^a   Pedro, Adriana Orcesi ^a   Pinto Neto, Aarão Mendes ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Hormone therapy; Knowledge attitude practice; Menopause; Post WHI; Postmenopausal women; Women's Health Initiative

Indexed keywords

ALPHA TOCOPHEROL; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CONJUGATED ESTROGEN; ISOFLAVONE; MEDROXYPROGESTERONE ACETATE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TIBOLONE; TRANQUILIZER;

ADULT; AGED; ARTICLE; BRAZIL; BREAST CANCER; CANCER RISK; DRUG DOSE REDUCTION; DRUG INDICATION; DRUG USE; FEAR; FEMALE; HEALTH CENTER; HORMONAL THERAPY; HUMAN; MALE; MEDICAL PRACTICE; MEDICAL SOCIETY; MEDICAL SPECIALIST; PHYSICIAN ATTITUDE; POSTMENOPAUSE; PRESCRIPTION; PROFESSIONAL KNOWLEDGE; QUESTIONNAIRE; SAMPLING ERROR; STATISTICAL ANALYSIS; TREATMENT WITHDRAWAL;

ADULT; AGED; ATTITUDE OF HEALTH PERSONNEL; BRAZIL; ESTROGEN REPLACEMENT THERAPY; FEMALE; GYNECOLOGY; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES; WOMEN'S HEALTH;

EID: 33846052684     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2006.06.022     Document Type: Article

References (36)

1. Mosca L., Collins P., Herrington D.M., et al. Hormone replacement therapy and cardiovascular disease-a statement for healthcare professionals from the American heart association. Circulation 104 (2001) 499-503
2. Bush T.S., Barret-Connor E., Cowan L.D., et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the lipid research clinics program follow-up study. Circulation 75 Suppl 6 (1987) 1102-1109
3. Barret-Connor E., Wingard D.L., and Criqui M.H. Postmenopausal estrogen use and heart disease risk factors in the. JAMA 262 (1989) 2095-2100
4. Matthews K.A., Meilahn E., Kuller L.H., Kelsey S.F., Caggiula A.W., and Wing R.R. Menopause and risk factors for coronary heart disease. N Engl J Med 321 (1989) 641-646
5. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280 (1998) 605-613
6. Grady D., Herrington D., Bittner V., et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 288 (2002) 49-57
7. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal, women. Principal results from the Women's Health Initiative randomized controlled, trial. JAMA 288 (2002) 321-333
8. Alving B. NIH asks participants in Women's Health Initiative estrogen-alone study to stop study pills, begin follow-up phase. South Med J 97 (2004) 425-426
9. Heitmann C., Greiser E., and Doren M. The impact of the Women's Health Initiative randomized controlled trial 2002 on perceived risk communication and use of postmenopausal hormone therapy in Germany. Menopause 12 (2005) 363-365
10. Hoffmann M., Hammar M., Kjellgren K.I., Lindh-Astrand L., and Brynhildsen J. Changes in women's attitudes towards and use of hormone therapy after HERS and WHI. Maturitas 52 (2005) 11-17
11. IMS Health. Information Management and Client Services. Research Latin America. Available at: http://www.imshealth.com/ims/portal/front/indexC/0,2773,6266_43950650_0,00.html. Accessed January 18, 2006.
12. Blumel J.E., Castelo-Branco C., Chedraui P.A., et al. Patients' and clinicians' attitudes after the Women's Health Initiative. Menopause 11 (2004) 57-61
13. Neyro M., Cancelo M.J., Quereda F., and Palacios F. Relevance of the results of the Women's Health Initiative on the prescription of hormone therapy in Spain. Climateric 8 (2005) 36-48
14. Nassar A.H., Essamad H.M., Awwad J.T., Khoury N.G., and Usta I.M. Gynecologists' attitudes towards hormone therapy in the post "Women's Health Initiative" study era. Maturitas 52 (2005) 18-25
15. North American Menopause Society. Recommendations for estrogen and progestogen use in peri- and postmenopausal women: October 2004 position statement of the North American Menopause Society. Menopause 11 6 (2004) 589-600
16. International Menopause Society. Guidelines for hormone treatment of women in the menopausal transition and beyond position statement by the Executive Committee of the International Menopause Society. Climacteric 7 (2004) 333-337
17. IBOPE Group. Available at: http://www.ibope.com.br/. Accessed January 25, 2006.
18. Machado R.B., Fernandes C.E., Maia E., Melo N.R., and Baracat E.C. Hormone therapy following the Women's Health Initiative (WHI) study: perception of gynecologists in Brazil. Minerva Ginecol 57 (2005) 563-568
19. Barros A.J., and Hirakata V.N. Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol 3 (2003) 21
20. Beral V., and Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 9382 (2003) 419-427
21. IBGE Instituto Brasileiro de Geografia e Estatística. Available at: http://www.ibge.gov.br/cidadesat/topwindow.htm?1. Accessed January 25, 2006.
22. Filho A.S., Soares Junior J.M., Arkader J., Maciel G.A., and Baracat E.C. Attitudes and practices about postmenopausal hormone therapy among female gynecologists in Brazil. Maturitas 51 (2005) 146-153
23. Burger H. Hormone replacement therapy in the post-Women's Health Initiative era. Report a Meeting held in Funchal, Madeira, February 24-25, 2003. Climacteric 2003;6 Suppl 1:11-36.
24. Klaiber E.L., Vogel W., and Rako S. A critique of the Women's Health Initiative hormone therapy study. Fertil Steril 84 (2005) 1589-1601
25. Speroff L. Alternative therapies for postmenopausal women. Int J Fertil Women Med 50 (2005) 101-114
26. Haimov-Kochman R., Hochner-Celnikier D., Haimov-Kochman R., and Hochner-Celnikier D. Hot flashes revisited: pharmacological and herbal options for hot flashes management. What does the evidence tell us?. Acta Obstet Gynecol Scand 84 (2005) 972-979
27. Sondergaard K.M., Hindsberger C., Toft U., Adser L., Damsgaard J.J., and Hvas A.C. Menopause, hormone therapy and alternative medicine: a cross-sectional study in Roskilde County in 1998. Ugeskr Laeger 167 (2005) 3185-3189
28. Dobson R. Popular herbal remedy for hot flushes is no better than placebo. Br Med J 331 7522 (2005) 924
29. Speroff L. WHI trial: it's time to be critical!. Am J Obstet Gynecol 189 (2003) 621-626
30. Grodstein F., Manson J.E., and Stampfer M.J. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) 15 (2006) 35-44
31. Doren M., Nilsson J.A., and Johnell O. Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis. Hum Reprod 18 (2003) 1737-1746
32. Wells G., Tugwell P., Shea B., et al. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 23 (2002) 529-539
33. Doren M. An assessment of hormone replacement therapy to prevent postmenopausal osteoporosis. Osteoporos 9 Suppl 2 (1999) S53-S61
34. IBOPE Group. Available at: http://www.ibope.com.br/. Accessed January 25, 2006.
35. McIntosh J., and Blalock S.J. Effects of media coverage of Women's Health Initiative study on attitudes and behavior of women receiving hormone replacement therapy. Am J Health Syst Pharm 62 (2005) 69-74
36. Barber C.A., Margolis K., Luepker R.V., and Arnett D.K. The impact of the Women's Health Initiative on discontinuation of postmenopausal hormone therapy: the Minnesota Heart Survey. J Womens Health (Larchmt) 13 (2004) 975-985